qNovel treatments for anal cancer are showing real promise, with the potential to improve survival rates and quality of life. This page explores some of the most promising new treatments, how they work, their status in the UK, and how patients may be able to access them.
Nivolumab
Nivolumab is a drug that helps the immune system destroy cancer cells. It uses immunotherapy, which is a treatment that helps your own immune system recognize and fight diseases like cancer more effectively.
How does it work?
Nivolumab is an immunotherapy drug that belongs to a class known as immune checkpoint inhibitors. These treatments help the immune system recognize and attack cancer cells by blocking proteins that stop immune cells from working properly. In anal cancer, Nivolumab has shown the ability to stimulate the body’s immune defenses to target and destroy cancerous cells, particularly in advanced or metastatic cases.
What is the status of Nivolumab?
In 2017, a study published in The Lancet by researchers at MD Anderson Cancer Center found that Nivolumab produced a response in 24% of patients with metastatic anal cancer. The treatment was also well tolerated with relatively few side effects.
The Anal Cancer Foundation helped co-fund this pivotal research. While not yet standard treatment in the UK, Nivolumab is being studied further in clinical trials and may be an option for patients with advanced or treatment-resistant disease.
Immunotherapies
How does Immunotherapy work?
Immunotherapy works by harnessing the body’s own immune system to fight cancer. Unlike chemotherapy, which attacks all rapidly dividing cells, immunotherapy targets the cancer more selectively, which may reduce some of the unwanted side effects. Types of immunotherapy include checkpoint inhibitors like Nivolumab and other agents that enhance immune response.
What is the status of immunotherapies for anal cancer?
Immunotherapy is a rapidly evolving field, with several new drugs and treatment approaches under investigation for anal cancer. While these therapies are not yet routinely offered for early-stage cases, they may be considered for people with recurrent or advanced disease, or as part of a clinical trial. Ongoing research is looking at combining immunotherapy with chemotherapy or radiation to improve outcomes.
Upcoming Studies
Researchers are now exploring how novel treatments like Nivolumab might work even better when combined with other drugs. Trials are underway to test combinations of immunotherapy agents and traditional treatments, aiming to strengthen their effectiveness. These studies may offer new options for patients whose cancer has returned or hasn’t responded to standard care.
If you think you might be eligible for a clinical trial or would like to explore access to these treatments, we encourage you to contact us for more information. You can also speak to your cancer team or visit ClinicalTrials.gov for a list of ongoing studies.
FAQs
The FAQs and content below were generated by ChatGPT as inspiration. Relevant questions may be used where appropriate.
Some newer treatments are already approved for particular situations, while others are still being studied. These answers explain the differences and what to discuss with your cancer care team.
What is targeted therapy, and how does it differ from chemotherapy?
Targeted therapy acts on particular molecules that help cancer cells grow. Traditional chemotherapy often damages cells as they divide, including some healthy cells. A targeted medicine can still cause serious side effects, so it is not automatically safer.
For anal cancer, a targeted medicine may be considered only in a specific situation supported by evidence, a tumor test or a clinical trial. Ask which medicine is being discussed, why it may help and whether it is approved for your situation.
Are there any clinical trials available for novel anal cancer treatments?
Yes, many clinical trials are exploring new drugs, treatment combinations and advanced radiation techniques for anal cancer. Patients can check with their oncologists or visit resources such as ClinicalTrials.gov to find ongoing studies for which they may be eligible.
A study’s status and eligibility can change. Taking part does not guarantee that you will benefit or receive a new medicine. Your team should explain what participation involves and how it compares with standard care.
What is proton beam therapy, and can it be used for anal cancer?
Proton beam therapy is a type of radiation that delivers highly precise doses to cancer cells while minimising damage to surrounding healthy tissue. Although it is not yet widely used for anal cancer, research is ongoing to determine its effectiveness in reducing side effects compared with traditional radiation therapy.
A potential advantage in radiation delivery does not prove that proton treatment is better for patients. It is not a routine replacement for standard radiation. Ask your radiation specialist whether there is a reason to consider it in your case or through a clinical trial.
Can novel treatments be used instead of chemotherapy and radiation?
For most stage I to III anal squamous cell cancers, chemotherapy with radiation remains the usual treatment. A newer treatment is not automatically an appropriate substitute.
For adults with anal canal squamous cell cancer, US approval includes retifanlimab (Zynyz) with carboplatin and paclitaxel when cancer has returned locally and cannot be removed by surgery, or has spread to distant organs. Retifanlimab is also approved alone for cancer that has returned or spread after platinum chemotherapy stops working or cannot be tolerated. Access varies by country.
Other approaches may be available through clinical trials. Ask whether the proposed treatment is approved, used outside its approved indication or still being studied.
What are the potential side effects of novel anal cancer treatments?
Side effects depend on the treatment. They may include fatigue, rash, diarrhea, nausea or other problems. Immunotherapy can cause the immune system to inflame healthy organs, including the lungs, bowel, liver or hormone-producing glands. These effects can be serious and require prompt assessment.
Tell your team about new symptoms, including those that develop after treatment has ended. Ask for written instructions explaining which symptoms require an urgent call. A newer or more targeted treatment does not necessarily have fewer side effects.
Who is eligible for novel treatments for anal cancer?
Eligibility depends on the cancer’s type and stage, previous treatment, general health and the specific medicine or study. Some options require particular tumor-test results, but genetic markers are not required for every immunotherapy.
Approved medicines and clinical trials have different eligibility rules. Your team can explain whether an option is suitable, what benefit is expected and how to access it.
Want to stay informed?
Sign up for our newsletter to receive updates on the latest research, treatment options, and ways to support the anal cancer community.
Need support or guidance?
Contact us today - we’re here to help.
We're here to empower thrivers and the anal cancer community. But we can't do it without your support.
